Leukaemia Trial, Recruiting (NCT06548152)

Leukaemia Trial, Recruiting NCT06548152 Sponsor: AstraZeneca Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT06548152 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are already enrolled in a database called PLATON
People who are 18 years of age or older
People who have been diagnosed with a type of blood cancer called CLL and have not previously received any treatment for it, but are currently being treated with a medicine called acalabrutinib (either on its own or combined with another medicine called obinutuzumab) in a standard clinical setting
People who are comfortable with their health information, already collected as part of the PLATON study, being used for research purposes
People who started treatment with acalabrutinib but stopped taking it before 12 months have passed

Who may not be able to join:

People who are pregnant
People who are under legal protection or guardianship arrangements (confirm with trial site)
People who are 18 or older but are unable to communicate whether they object to their data being used
People who have previously received other treatments for CLL before this study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06548152

Sponsor: AstraZeneca

Phase: Not Applicable

Status: Recruiting

Condition: Leukaemia

Trial contact: 1-877-240-9479

More information: https://clinicaltrials.gov/study/NCT06548152

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are already enrolled in a database called PLATON
People who are 18 years of age or older
People who have been diagnosed with a type of blood cancer called CLL and have not previously received any treatment for it, but are currently being treated with a medicine called acalabrutinib (either on its own or combined with another medicine called obinutuzumab) in a standard clinical setting
People who are comfortable with their health information, already collected as part of the PLATON study, being used for research purposes
People who started treatment with acalabrutinib but stopped taking it before 12 months have passed

Who may not be able to join:

People who are pregnant
People who are under legal protection or guardianship arrangements (confirm with trial site)
People who are 18 or older but are unable to communicate whether they object to their data being used
People who have previously received other treatments for CLL before this study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

AstraZeneca

Registry

ClinicalTrials.gov

Start date

28 April 2025

Est. completion

31 December 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

To measure QoL score of CLL patients treated with acalabrutinib, from treatment initiation and up to 12 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov